• Issue
    Volume 51, Issue 10
    October 2021


Free Access

Issue Information

  • Pages: 1255-1257
  • First Published: 29 September 2021


Free Access

Unmet needs in food allergy

  • Pages: 1258-1259
  • First Published: 29 September 2021


Free Access

BSACI 2021 guideline for the management of egg allergy

  • Pages: 1262-1278
  • First Published: 29 September 2021


Basic Mechanisms in Allergic Disease

Open Access

Characterization of anaphylaxis reveals different metabolic changes depending on severity and triggers

  • Pages: 1295-1309
  • First Published: 26 July 2021
Description unavailable

For the first time, the metabolic profile of anaphylaxis in a real-life set-up was characterized and provide evidence that different triggers (Food and Drug) and severity (Moderate and Severe) induce differential metabolic changes improving clinical practice. Eighteen episodes of anaphylaxis with a full clinical characterization were analyzed by metabolomics. The time points were: acute phase (T1), recovery phase (T2) and basal state (T0). Basal status might identify high risk patients, thus opening new ways to understand, diagnose and treat anaphylaxis

Small nucleolar RNA networks are up-regulated during human anaphylaxis

  • Pages: 1310-1321
  • First Published: 06 July 2021
Description unavailable

Small nucleolar RNA (snoRNA) upregulation is a unique feature of acute anaphylaxis in humans, not a general feature of systemic inflammation. SnoRNA upregulation may be associated with anaphylaxis reaction severity. Further investigation is needed to determine the diagnostic significance of snoRNAs. qRT-PCR (quantitative reverse transcription-polymerase chain reaction).

Clinical Allergy

Open Access

Allergen extract- and component-based diagnostics in children of the ALLIANCE asthma cohort

  • Pages: 1331-1345
  • First Published: 15 June 2021
Description unavailable

Among 106 young children (mean age 4 years) of the All Age Asthma (ALLIANCE) cohort, ImmunoCAP™ sx1 and fx1 mixes, the ImmunoCAP ISAC™ 112 microarray, and a Euroline™ panel showed good analytical and diagnostic concordance in four common clinical scenarios. Our results caution that the identification of larger numbers of sensitizations by more comprehensive multiplex approaches may not improve clinical utility of sIgE testing in this age group.

Experimental Models of Allergic Disease

Intranasal delivery of allergen in a nanoemulsion adjuvant inhibits allergen-specific reactions in mouse models of allergic airway disease

  • Pages: 1361-1373
  • First Published: 17 May 2021
Description unavailable

The ability of intranasal vaccines to modulate allergic immune responses and inflammation in the lung was studied in two distinct models of allergic airway disease. Mice were sensitized to ovalbumin or cockroach allergen and subsequently received three immunizations with allergen in nanoemulsion adjuvant. Nanoemulsion vaccines modulated the allergen-specific cytokine milieu in the lungs to suppress Th2 cytokine production, alarmin expression and recruitment of ILC2s. The immune modulation in the lungs was associated with protection from allergen challenge-induced inflammation and reactivity.


Open Access

Poor understanding of allergen labelling by allergic and non-allergic consumers

  • Pages: 1374-1382
  • First Published: 20 July 2021
Description unavailable

‘Food labels are a crucial source of information for allergic consumers, but despite ingredient declaration legislation, allergic reactions frequently occur. We evaluated common allergy information on foods in two controlled experimental studies. Allergic consumers attribute lower risks to products with PAL than consumers without FA, different risks are attributed to different PAL wordings especially by consumers with higher levels of Health Literacy, and less than 50% of participants judge allergy information to be clear. Better allergy information is called for.’